Business Description
Vivimed Labs Ltd
ISIN : INE526G01021
Total Employee Number:
586Compare
Compare
Traded in other countries / regions
532660.India IPO Date
2005-08-17Description
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.13 | |||||
Equity-to-Asset | -0.05 | |||||
Debt-to-Equity | -8.01 | |||||
Debt-to-EBITDA | -34.83 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.11 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -21.1 | |||||
3-Year EBITDA Growth Rate | -7.3 | |||||
3-Year EPS without NRI Growth Rate | 21.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.42 | |||||
9-Day RSI | 24.63 | |||||
14-Day RSI | 31.55 | |||||
3-1 Month Momentum % | 10.27 | |||||
6-1 Month Momentum % | -70.28 | |||||
12-1 Month Momentum % | 30.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.78 | |||||
Quick Ratio | 0.66 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 498.16 | |||||
Days Sales Outstanding | 366.33 | |||||
Days Payable | 384.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -5.33 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 49.73 | |||||
Operating Margin % | -36.36 | |||||
Net Margin % | -41.8 | |||||
EBITDA Margin % | -13.19 | |||||
FCF Margin % | -7.51 | |||||
OCF Margin % | -2.09 | |||||
ROA % | -3.76 | |||||
ROIC % | -3.18 | |||||
3-Year ROIIC % | 1.21 | |||||
ROC (Joel Greenblatt) % | -7.77 | |||||
ROCE % | -6.12 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.6 | |||||
EV-to-EBIT | -12.33 | |||||
EV-to-EBITDA | -34.75 | |||||
EV-to-Revenue | 4.58 | |||||
EV-to-FCF | -60.99 | |||||
Price-to-GF-Value | 2.26 | |||||
Price-to-Projected-FCF | 0.04 | |||||
Price-to-Median-PS-Value | 1.91 | |||||
Earnings Yield (Greenblatt) % | -8.11 | |||||
FCF Yield % | -13.06 | |||||
Forward Rate of Return (Yacktman) % | 358.34 |
Vivimed Labs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vivimed Labs Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 5:1 Stock Split | 2016-04-06 | 83.47 (-0.65%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Vivimed Labs Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers